Eli Lilly eyes 2027 India launch for Foundayo, subject to regulatory approval
Eli Lilly expects Foundayo to launch in India in 2027, subject to regulatory approval. CEO David Ricks said Mounjaro sales continue growing in volume and value despite cheaper generics, while India could become one of Lilly’s top five markets.
Read the source at CNBC-TV18 · CompaniesThe numbers
| Mounjaro monthly price: | ₹13,000 to ₹25,000 a month |
|---|---|
| Semaglutide branded generics monthly price: | ₹1,500 to about ₹5,500 |
| India market ranking ambition: | top five |
| Indian supplier investment commitment: | a billion dollars |
Why it matters to operators and investors
Prepare India pharmacy and distribution plans for Foundayo’s potential 2027 launch, keeping rollout commitments contingent on regulatory approval.
What to watch next
- An Indian regulatory filing or approval announcement for Foundayo.
- Confirmation or revision of the expected 2027 launch.
- Mounjaro India volume and value growth after further generic competition.
- New semaglutide generic launches or announced price cuts.
- Disclosure of India's progress toward Lilly's top five markets.
The counter-case
A conditional 2027 launch is not an approval or a revenue commitment, and Mounjaro's momentum does not establish demand for Foundayo. Cheaper semaglutide generics could pressure pricing and retention; growing sales volume and value do not establish improving profitability or market share. India's potential top-five ranking remains a management forecast.